Status:
COMPLETED
Effects of Guided Written Disclosure Protocol on Psychological Distress and Positive Functioning in Persons With Skin Diseases: a Randomized-controlled Trial
Lead Sponsor:
European University of Rome
Collaborating Sponsors:
IRCSS Istituto Dermopatico dell'Immacolata, Fondazione Luigi Maria Monti
Conditions:
Psychological Distress
Emotional Stress
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We conducted a randomized-controlled trial of Guided Written Disclosure Protocol for dermatological patients with the aim of reducing psychological distress, expressive suppression, and skin-related s...
Detailed Description
Sample size assessment: A recent meta-analysis reported a study which showed that Guided Written Disclosure Protocol reach on effect size of 0.89 on psychosocial outcomes (Gidron et al., 2002; Mogk et...
Eligibility Criteria
Inclusion
- Age over 18 years;
- Diagnosis of psoriasis or systemic sclerosis by a board-certified dermatologist.
Exclusion
- Patients with certified mental disorders (e.g., psychotic illness, major depressive disorder)
- Patients undergoing psychotherapy for at least 6 months in the last 3 years;
- Patients who currently receive psychopharmacological treatment.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04739228
Start Date
July 1 2017
End Date
March 1 2020
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCSS Istituto Dermopatico dell'Immacolata, Fondazione Luigi Maria Monti
Rome, Italy, 00167